SEATTLE, WA, September 11, 2024 — ÃÜÌÒÊÓƵ, Inc. (ÃÜÌÒÊÓƵ), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, today announced that Ryan Crisman, Ph.D., Co-Founder and Chief Technical Officer of ÃÜÌÒÊÓƵ, will present on the growing promise of ÃÜÌÒÊÓƵ’s in vivo clinical-stage science and manufacturing strategy at the being held September 17-20, 2024, in Boston, Massachusetts.
Details of the presentations can be found below:
¹ó´Ç°ù³¾²¹³Ù:ÌýCompany Presentation
°Õ¾±³Ù±ô±ð:ÌýThe Make vs Buy Decision for Early Stage Biotechs in the Cell & Gene Therapy Space: ÃÜÌÒÊÓƵ’s Experience
Track:Â Supply Chain & Clinical Operations
¶Ù²¹³Ù±ð:ÌýWednesday, September 18, 2024
°Õ¾±³¾±ð:Ìý11:40 am ET
Format: Panel Discussion
Title: Highlighting the Next Generation Opportunity & Potential for In Vivo Engineered Cell Therapies
Track: Discovery Track
Date: Thursday, September 19, 2024
Time: 12:25 pm ET
About ÃÜÌÒÊÓƵ
ÃÜÌÒÊÓƵ, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CART cell therapies in both oncology and autoimmunity. ÃÜÌÒÊÓƵ’s VivoVecâ„¢ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. ÃÜÌÒÊÓƵ believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with ÃÜÌÒÊÓƵ on LinkedIn and visit .
Investors
Stephen Jasper
Gilmartin Group, LLC
stephen@gilmartinir.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com